Valmet Partners with Sofidel America for Advanced Tissue Line
Valmet Enhances Sofidel America's Ultra-Premium Tissue Production
Valmet Oyj proudly announces its collaboration with Sofidel America to establish a sophisticated new tissue line designed to address the increasing demand for ultra-premium tissue products. This venture will enable Sofidel America to broaden its production capabilities substantially, meeting the needs of consumers across North America more effectively.
Investing in Advanced Technology
The installation of the Advantage ThruAir tissue line marks a significant investment from Sofidel, reflecting their commitment to quality and innovation in the market. Valmet's comprehensive supply consists of not just the tissue line but also an advanced automation package, flow control systems, and innovative Industrial Internet solutions that enhance production efficiency.
A Strong Partnership
Valmet and Sofidel America have enjoyed a collaborative relationship for over thirty years. Currently, Sofidel operates 20 tissue lines, demonstrating their extensive capacity to produce high-quality products. The latest project, an Advantage DCT line, was successfully launched at the company's Circleville mill in recent months, showcasing the effective teamwork and mutual trust between the two companies.
Meeting Growing Consumer Demand
Luigi Lazzareschi, CEO of Sofidel, expressed excitement about the new line, stating, “This significant investment anchors us deeper in the United States and enhances our capabilities to meet customer demands for premium tissue products. The Advantage ThruAir technology represents industry-leading standards in efficient production methods.” His remarks emphasize the expectation for continued success based on solid teamwork through their joint projects.
Technical Details of the New Line
The new tissue paper production line boasts a width of 5.6 meters with an impressive annual capacity of 75,000 tons. It has been specifically optimized to conserve fibers while delivering outstanding paper quality, meeting the high standards customers expect.
Comprehensive Delivery Scope
Valmet's order encompasses a complete range of services, including Mill Engineering and Stock preparation equipment. The cutting-edge Advantage ThruAir 200 tissue machine will play a crucial role in this project, backed by an automation package featuring the Valmet DNA Distributed Control System (DCS) and integrated machine condition monitoring.
Quality Control and Performance Monitoring
In addition, Valmet will provide a Quality Control System (QCS) and a Web Monitoring System (WMS) for enhancing product quality and ensuring optimal operational performance. The company's flow control and Industrial Internet solutions are also included, demonstrating Valmet's commitment to supporting its partners with top-tier technology endpoints.
About Sofidel Group
The Sofidel Group is a leading global manufacturer of paper for hygienic and domestic use. Established in 1966, the Group operates subsidiaries in 13 countries, employs over 9,500 staff, and achieved remarkable consolidated net sales figure in its latest financial reports. The company’s commitment to sustainability and innovation in production lines positions them at the forefront of the industry.
Operational Footprint
Sofidel America operates 14 production facilities, strategically located across various states, which enhances their distribution and response time to market demands. This operational spread illustrates Sofidel’s determination to maintain an efficient supply chain while ensuring customer satisfaction.
Continued Leadership and Innovation
Valmet is a well-respected global technology leader that serves diverse process industries. With a long history exceeding 225 years, they stand out in providing innovative technologies and services throughout various production lifecycles. Their dedication to sustainability and customer collaboration has established them as a trusted partner in numerous sectors.
Frequently Asked Questions
What is the new technology being introduced by Sofidel America?
The new technology being introduced is the Advantage ThruAir tissue line, aimed at enhancing production capabilities and meeting consumer demand for ultra-premium products.
How has Valmet contributed to this project?
Valmet is supplying the complete tissue production line, including advanced automation and quality control features, to significantly improve production efficiency.
What is the expected production capacity of the new line?
The new Advantage ThruAir tissue line is designed to produce an annual capacity of 75,000 tons of tissue paper.
What sets Sofidel America apart in the tissue market?
Sofidel America's extensive experience, dedication to sustainability, and innovative production techniques position them as a leader in the ultra-premium tissue market.
When is the new line scheduled to start operations?
The start-up of the new tissue line is planned for the second quarter of 2028, marking a pivotal moment for Sofidel America’s production capabilities.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
